Posted by Michael Wonder on 18 Nov 2022
Calliditas' partner Everest Medicine's new drug application for Nefecon is accepted by the China NMPA
15 November 2022 - Calliditas Therapeutics today announced that the Chinese regulatory authority NMPA has accepted Everest Medicines' new drug application for Nefecon.
The acceptance brings Nefecon, approved and marketed in the US under the name Tarpeyo and in the EU as Kinpeygo, an important step closer to potentially becoming the first ever approved therapeutic option indicated for primary IgAN treatment in China.
